This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

PETER J. SPÄTH, PHD
Bern, Switzerland

BRUNELLO WÜTHRICH, MD
Zurich, Switzerland

LUKA MATTER, MD
St Gallen, Switzerland

MICHAEL LOOS, PHD; JOCHEM ALSENZ, PHD
Mainz, West Germany

Arch Intern Med. 1989;149(5):1213-1216.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—Two types of acquired angioedema (AAE) are recognized today; type I with low levels of functional C1-inhibitor (C1-INH), no detectable autoantibody to C1-INH, and an underlying disease, such as a B-cell disorder,¹ and type II with moderately depressed functional C1-INH levels, anti–C1-INH autoantibodies in circulation without detectable underlying disease.^2-4 We describe the long-term follow-up of a patient with AAE type II.

Report of a Case.—A woman, born in 1921, first presented with an attack of angioedema in December 1980. Based on complement studies and patient history, an AAE was diagnosed in December 1981. Therapy with danazol and later with tranexamic acid was initiated. Recurrent life-threatening attacks with need for the infusion of fresh frozen plasma indicated ineffectiveness of these therapies. Several investigations failed to detect a malignant neoplasia or a dysproteinemia. However, in August 1983, a giant subserous myoma of the fundus of the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?